{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:11:42Z","timestamp":1790799102080,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Growth Hormone & IGF Research"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ghir.2023.101548","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T03:08:06Z","timestamp":1689995286000},"page":"101548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Administration of insulin like growth factor I (IGF I) lowers serum lipoprotein(a)-impact on atherosclerotic cardiovascular disease"],"prefix":"10.1016","volume":"71","author":[{"given":"Zvi","family":"Laron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haim","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ghir.2023.101548_bb0005","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man - the Lp system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol. Microbiol. Scand."},{"issue":"3","key":"10.1016\/j.ghir.2023.101548_bb0010","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1542\/peds.89.3.401","article-title":"Early expression of the apolipoprotein(a) gene: relationships between infants\u2019 and their parents\u2019 serum apolipoprotein(a) levels","volume":"89","author":"Wang","year":"1992","journal-title":"Pediatrics."},{"issue":"8","key":"10.1016\/j.ghir.2023.101548_bb0015","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein(a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ghir.2023.101548_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0021-9150(90)90177-K","article-title":"Lipoprotein(a): structure, properties and possible involvement in thrombogenesis and atherogenesis","volume":"85","author":"Bewu","year":"1990","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.ghir.2023.101548_bb0025","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein(a) as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ghir.2023.101548_bb0030","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on lipoprotein(a): a call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.ghir.2023.101548_bb0035","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation."},{"issue":"4","key":"10.1016\/j.ghir.2023.101548_bb0040","first-page":"398","article-title":"Lipoprotein Lp(a). A risk factor for myocardial infarction","volume":"8","author":"Hoefler","year":"1988","journal-title":"Atheriosclerosis."},{"key":"10.1016\/j.ghir.2023.101548_bb0045","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ghir.2023.101548_bb0050","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA."},{"issue":"2019","key":"10.1016\/j.ghir.2023.101548_bb0055","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ghir.2023.101548_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2022.101503","article-title":"Increase of serum lipoprotein (a), an adverse effect of growth hormone treatment","volume":"67","author":"Laron","year":"2022","journal-title":"Growth Hormon. IGF Res."},{"key":"10.1016\/j.ghir.2023.101548_bb0065","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/mp.54.5.311","article-title":"Insulin-like growth factor 1 (IGF-1): a growth hormone","volume":"54","author":"Laron","year":"2001","journal-title":"Mol. Pathol."},{"key":"10.1016\/j.ghir.2023.101548_bb0070","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/BF00402285","article-title":"Improvement of lipid profile in type 2 (non-insulin-dependent) diabetes mellitus by insulin-like growth factor I","volume":"36","author":"Zenobi","year":"1993","journal-title":"Diabetologia."},{"key":"10.1016\/j.ghir.2023.101548_bb0075","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1530\/eje.0.1380189","article-title":"Effects of short-term treatment with insulin-like growth factor-I and growth hormone on serum lipoprotein (a) in growth hormone-deficient adults","volume":"138","author":"Bianda","year":"1998","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2023.101548_bb0080","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/01.ATV.15.7.847","article-title":"Hormonal regulation of serum lipoprotein(a) levels. Contrasting effects of growth hormone and insulin-like growth factor-I","volume":"15","author":"Olivecrona","year":"1995","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ghir.2023.101548_bb0085","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2265.1995.tb02699.x","article-title":"Recombinant human insulin-like growth factor-I decreases serum lipoprotein(a) concentrations in normal adult men","volume":"42","author":"Oscarsson","year":"1995","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ghir.2023.101548_bb0090","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0026-0495(96)90245-0","article-title":"Insulin-like growth factor-I decreases serum lipoprotein (a) during long-term treatment of patients with Laron syndrome","volume":"45","author":"Laron","year":"1996","journal-title":"Metabolism."},{"issue":"1","key":"10.1016\/j.ghir.2023.101548_bb0095","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50 mg\/dL (105 nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Atherioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ghir.2023.101548_bb0100","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S0140-6736(88)90236-X","article-title":"Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism","volume":"2","author":"Laron","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.ghir.2023.101548_bb0105","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1530\/eje.0.1310251","article-title":"Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type a","volume":"131","author":"Zenobi","year":"1994","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2023.101548_bb0110","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0021-9150(97)00110-X","article-title":"The effect of growth hormone replacement therapy for up to 12 months on lipoprotein composition and lipoprotein(a) in growth hormone-deficient adults","volume":"133","author":"Webster","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ghir.2023.101548_bb0115","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/apa.15948","article-title":"The history, physiology and treatment safety of growth hormone","volume":"111","author":"Tidblad","year":"2022","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ghir.2023.101548_bb0120","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2020.5199","article-title":"Association of childhood growth hormone treatment with long-term cardiovascular morbidity","volume":"175","author":"Tidblad","year":"2021","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.ghir.2023.101548_bb0125","doi-asserted-by":"crossref","DOI":"10.1007\/s11883-023-01113-2","article-title":"Lipoprotein apheresis: current recommendations for treating familial hypercholesterolemia and elevated lipoprotein (a)","author":"Safarova","year":"2023","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.ghir.2023.101548_bb0130","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"Suppl L","key":"10.1016\/j.ghir.2023.101548_bb0135","doi-asserted-by":"crossref","first-page":"L53","DOI":"10.1093\/eurheartj\/suaa135","article-title":"Lipoprotein(a) and PCSK9 inhibition: clinical evidence","volume":"22","author":"Ruscica","year":"2020","journal-title":"Eur. Heart J. Suppl."},{"issue":"4","key":"10.1016\/j.ghir.2023.101548_bb0140","article-title":"Effect of evolocumab on lipoprotein(a) and PCSK9 in healthy individuals with elevated lipoprotein(a) Level","volume":"7","author":"Afanasieva","year":"2020","journal-title":"J. Cardiovasc. Dev. Dis."},{"issue":"1","key":"10.1016\/j.ghir.2023.101548_bb0145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12872-020-01827-0","article-title":"Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes","volume":"21","author":"Li","year":"2021","journal-title":"BMC Cardiovasc. Disord."},{"issue":"3","key":"10.1016\/j.ghir.2023.101548_bb0150","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ghir.2023.101548_bb0155","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ghir.2023.101548_bb0160","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ghir.2023.101548_bb0165","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1253\/circj.CJ-20-0051","article-title":"Lipoprotein(a) and cardiovascular diseases - revisited","volume":"84","author":"Jang","year":"2020","journal-title":"Circ. J."},{"key":"10.1016\/j.ghir.2023.101548_bb0170","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.2022.5333","article-title":"The potential clinical benefit of lowering lipoprotein(a)","volume":"327","author":"Ference","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ghir.2023.101548_bb0175","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1159\/000527123","article-title":"The history of the insulin-like growth factor system","volume":"95","author":"Miller","year":"2022","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.ghir.2023.101548_bb0180","first-page":"105","article-title":"Insulin resistance in Laron syndrome (primary insulin like growth factor-I (IGF-I) deficinecy) and effect of IGF-I replacement therapy","volume":"19","author":"Laron","year":"1997","journal-title":"J. Pediat. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2023.101548_bb0185","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2337\/diacare.29.04.06.dc05-1433","article-title":"High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database","volume":"29","author":"Soedamah-Muthu","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ghir.2023.101548_bb0190","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1210\/jc.2007-1756","article-title":"A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study","volume":"93","author":"Valkenburg","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2023.101548_bb0195","doi-asserted-by":"crossref","DOI":"10.1210\/er.2012-1003","article-title":"Cardio metabolic aspects of the polycystic ovary syndrome","volume":"33","author":"Randeva","year":"2012","journal-title":"Endocr. Rev."}],"container-title":["Growth Hormone & IGF Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637423000266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637423000266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T22:53:27Z","timestamp":1761087207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096637423000266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":39,"alternative-id":["S1096637423000266"],"URL":"https:\/\/doi.org\/10.1016\/j.ghir.2023.101548","relation":{},"ISSN":["1096-6374"],"issn-type":[{"value":"1096-6374","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Administration of insulin like growth factor I (IGFI) lowers serum lipoprotein(a)-impact on atherosclerotic cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"Growth Hormone & IGF Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ghir.2023.101548","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101548"}}